VivoSeq
Oncology

Stomach Neoplasm

32

Pipeline Programs↗

0

Active Trials↗

19

Companies Involved↗

Stomach Neoplasm is a moderately active landscape with 32 programs across 19 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Coherus Oncology, Inc., Innovent Biologics (Suzhou) Co. Ltd.. 15 therapies are approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

12/100

Completion Rate

N/A

Attrition Rate

N/A

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 2C

Coherus Oncology, Inc.

1 program

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2I

Imclone

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3E

Eastern Cooperative Oncology Group

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

66%

Small molecule

21 of 32 classified programs — the dominant modality here.

34%ALL OTHERSMonoclonal antibody1031%Protein / enzyme13%

Small molecule leads; the ring shows all 32 classified programs, each share of the total. Modality classified for 100% of 32 pipeline programs.

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)